Q2 roll call for mid-sized pharma, as companies face generics trough

Share this article:
First-half earnings are in for Allergan, Shire and UCB, with the three companies striking an upbeat tone on revenues, despite the generics trough.

Allergan sales rose 5%, to $1.5 billion for the quarter ended June 30, compared to sales of $1.4 billion for the same period last year. The company said in a statement Wednesday that specialty pharma had a 5% boost in sales over the same period last year, and medical devices also rose, outpacing last year's sales by 4%. Looking ahead, the company said it expects sales to be between $5.6 billion and $5.9 billion for the year. Leerink Swann analyst Seamus Fernandez said in his August 1 research note that the earnings forecast reflects some downward revisions, including a lower guidance for the firm's eye-pressure drop Lumigan, its filler franchises and its medical device divisions. Fernandez noted that a July survey of dermatologists and plastic surgeons indicated a sluggish Q2 for fillers like Botox, but about a 5% increase between July 2012 and 2013.

Shire's second-quarter results continued the positive turnover trend, despite the influx of generic Adderall XR from Watson into the ADHD marketplace. Sales were $1.2 billion for the quarter, a 16% increase over sales for the same period last year. Strong sellers included ADHD medicine Vyvanase, which had $266 million in sales, a 46% boost over sales for the same period last year. Sales of the Gaucher disease medication Vpriv were $83 million, up 31% over sales for the same period last year, and ADHD medication InTuniv had a 16% sales boost, rising to $70 million compared to sales for the same period in 2011. Adderall XR sales fell to $134 million, a 9% drop from sales during Q2 2011, an expected fall-off from the debut of Watson's copy cat (two authorized generic versions are made by Impax and Teva). The company said it still expects the brand to be a sales contributor, despite the lower-cost competition.

UCB didn't break out quarterly results Wednesday but did say things were going as expected. The Brussels-based drugmaker said its sales rose to $2.1 billion during the first two quarters, a 2% increase over sales for the same period last year. The company said sales of its Crohn's/RA drug Cimzia increased 46% over last year, at $256 million, while sales of the now-generic epilepsy drug Keppra fell to $545 million, a 12% drop from sales for the same period last year. The company said it expects sales of Cimzia, epilepsy drug Vimpat and Parkinson's disease/restless legs syndrome treatment Neupro to be the main drivers for the year's sales.
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?